UNLABELLED: Intraoperative radiotherapy (IORT) is continuously gaining ground in cancer treatment. However, there is currently no planning system associated with these devices, which precludes patient-specific dose delivery optimization. The objective of this study was the development and validation of a Monte Carlo simulation (MCS)-based dosimetry platform using the Intrabeam™ system. METHODS: After surgical resection of the tumor this system delivers a single dose fraction at the surface of an applicator irradiating the tumor bed through a 50 kV x-ray beam. The GATE MCS platform was used in this study combining the phase space obtained by modeling the x-ray source and the detailed modeling of the additional parts of the Intrabeam™ system. The model was validated by comparing simulated versus experimental measurements of depth dose curves (DDC) and isotropy. A clinical validation study was also carried out using patient computed tomography images. RESULTS: The mean deviation between measured and simulated DDC was 2.9% ± 4.4% and 5.9% ± 5.7% for the bare needle and the use of applicators, respectively. A good agreement with experimental measurements was also found in terms of dose isotropy with a maximum difference of 2.04% for the 40 mm diameter applicator. A patient study revealed a mean absolute deviation of 0.06 Gy between simulated and thermoluminescent dosimeters (TLD) measured skin doses. CONCLUSION: This study shows the potential of using the GATE MCS platform to model three-dimensional dose distributions of the Intrabeam™ system for use in IORT.
UNLABELLED: Intraoperative radiotherapy (IORT) is continuously gaining ground in cancer treatment. However, there is currently no planning system associated with these devices, which precludes patient-specific dose delivery optimization. The objective of this study was the development and validation of a Monte Carlo simulation (MCS)-based dosimetry platform using the Intrabeam™ system. METHODS: After surgical resection of the tumor this system delivers a single dose fraction at the surface of an applicator irradiating the tumor bed through a 50 kV x-ray beam. The GATE MCS platform was used in this study combining the phase space obtained by modeling the x-ray source and the detailed modeling of the additional parts of the Intrabeam™ system. The model was validated by comparing simulated versus experimental measurements of depth dose curves (DDC) and isotropy. A clinical validation study was also carried out using patient computed tomography images. RESULTS: The mean deviation between measured and simulated DDC was 2.9% ± 4.4% and 5.9% ± 5.7% for the bare needle and the use of applicators, respectively. A good agreement with experimental measurements was also found in terms of dose isotropy with a maximum difference of 2.04% for the 40 mm diameter applicator. A patient study revealed a mean absolute deviation of 0.06 Gy between simulated and thermoluminescent dosimeters (TLD) measured skin doses. CONCLUSION: This study shows the potential of using the GATE MCS platform to model three-dimensional dose distributions of the Intrabeam™ system for use in IORT.